<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01636024</url>
  </required_header>
  <id_info>
    <org_study_id>D3740C00001</org_study_id>
    <nct_id>NCT01636024</nct_id>
  </id_info>
  <brief_title>To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594</brief_title>
  <official_title>A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Ascending Inhaled Doses of AZD7594 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile and look at levels of AZD7594 and
      biomarkers in blood when the drug is administered inhaled to healthy subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study
      to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and
      Multiple Ascending Inhaled Doses of AZD7594 in Healthy Male Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile in terms of adverse events, ECG, blood pressure, pulse, physical examination, body temperature, haematology, clinical chemistry, urinalysis and spirometry.</measure>
    <time_frame>Screening to 13 days post last dose.</time_frame>
    <description>No statistical tests will be performed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single dose pharmacokinetics (PK) of AZD7594 in terms of : Cmax, tmax, λz, t1/2λz, AUC(0-last), AUC(0-24), AUC, CL/F, Vz/F, MRT, Cmax/D, AUC/D, AUC(0-24)/D.</measure>
    <time_frame>pre-dose and at 5, 15 and 30 minutes and 1, 2, 4, 6, 9, 12, 18, 24, 36 and 48 hours post-dose. From cohort four 72 and 96 hours post-dose samples will also be taken.</time_frame>
    <description>Cmax- max plasma concentration;tmax-Time to max plasma concentration,λz- terminal rate constant;t1/2λz - Terminal half-life;AUC(0-24) - Area under the plasma concentration time curve from zero to 24 hours;AUC- Area under the plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple dose PK of AZD7594 in terms of: Cmax, tmax, λz, t1λz, AUC(0-last), AUC(0-24), AUC, CL/F, Vz/F, MRT, Cmax/D, AUC/D,AUC(0-24)/D, Cavg, %Fluctuation, Rac(Cmax) and Rac(AUC(0-24) and time-dependency (AUC(0-24) and AUC)</measure>
    <time_frame>pre-dose and at 5, 15 and 30 min and 1, 2, 4, 6, 9, 12, 18, 24, 48, 72 hours and 96 h post-dose. Days 6-15: Pre-dose samples only.From day 16: pre-dose and 5, 15 and 30 min and 1, 2, 4, 6, 9, 12, 18, 24, 36 and 48 h post-dose.</time_frame>
    <description>CL/F- Apparent plasma clearance;Vz/F- Apparent volume of distribution during terminal phase; MRT- Mean residence time; Rac Cmax-Accumulation ratio of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of AZD7594 following a single dose in terms of: 24-hour plasma cortisol</measure>
    <time_frame>screening and on the dosing day at the following time points 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24. On the dosing day also at 36 and 48 hours post dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of AZD7594 following a multiple doses in terms of: 24-hour plasma cortisol</measure>
    <time_frame>screening and days 1 and 16 at the following time points 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 hours. On day 1 also at 36 and 48 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of AZD7594 following multiple doses in terms of: Plasma cortisol after adrenocorticotropic hormone stimulation</measure>
    <time_frame>screening and day 17 at 30 minutes and 1 hour post tetracosactide injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of AZD7594 following multiple doses in terms of: Plasma dehydroepiandrosterone sulphate, plasma 4β-OH-cholesterol, and plasma osteocalcin</measure>
    <time_frame>screening and day 17</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Safety</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Pharmacodynamics of AZD7594</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will participate in 1 of up to 9 groups in Part A (single ascending dose part) or 1 of 4 groups in Part B (multiple ascending dose part). Ratio of subjects receiving AZD7594 versus placebo is 6:2 in part A and 6:3 in Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will participate in 1 of up to 9 groups in Part A or 1 of 4 groups in Part B. Ratio of subjects receiving AZD7594 versus placebo is 6:2 in part A and 6:3 in Part B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD7594</intervention_name>
    <description>Suspension inhaled via Spira nebuliser</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match</intervention_name>
    <description>Matching placebo inhaled via Spira nebuliser</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers aged 18-45 years inclusive with suitable veins for cannulation
             or repeated vein puncture

          -  Have a body mass index (BMI) between 18 and 30 kg/m2 and weight between 50 and 100 kg
             (inclusive)

          -  Be able to inhale from the Spira nebuliser used in the study

          -  Be willing to use a condom with spermicide to prevent pregnancy and drug exposure of a
             female partner

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder

          -  Current smokers

          -  Any clinically relevant abnormal findings
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carin Jorup, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, Molndal Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2012</study_first_submitted>
  <study_first_submitted_qc>July 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2012</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1,</keyword>
  <keyword>healthy volunteers,</keyword>
  <keyword>safety,</keyword>
  <keyword>tolerability,</keyword>
  <keyword>pharmacokinetics,</keyword>
  <keyword>pharmacodynamics,</keyword>
  <keyword>single ascending dose study,</keyword>
  <keyword>multiple</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

